“…So far, it does not seem possible to say whether the situa tion is similar in Europe, where the system is based on donor groups consisting of re peatedly donating persons under continuous screening including ALT testing in most European countries, with a consequently low risk of transmission of hepatitis [27]: in a retrospective investigation of all donors who had been implicated in altogether 12 cases of PTH B in West Germany, Fiedler [12] found only 1 donor positive for anti-HBc. In con trast to this are the results of a prospective controlled study done by Katchaki et al [22] for anti-HBc IgM and HBeAg as well as bor derline positive test for anti-HBs do not per mit any conclusion with regard to persisting virus replication respectively high infectivity [11,35], Nevertheless, the donor had already been implicated into a case of clini cally manifest hepatitis type B years ago, and furthermore, still another recipient of his blood showed a massive booster reaction in anti-HBs. In this last case, that is well docu mented, a passive administration of antiHBs or transfusion of HBsAg-positive re spectively infectious material through other donors or blood derivatives can definitely be excluded.…”